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ABSTRACT
Background and aim MartineProbst syndrome (MPS)
is a rare X-linked disorder characterised by deafness,
cognitive impairment, short stature and distinct
craniofacial dysmorphisms, among other features. The
authors sought to identify the causative mutation for
MPS.
Methods and results Massively parallel sequencing in
two affected, related male subjects with MPS identiﬁed
a RAB40AL (also called RLGP) missense mutation
(chrX:102,079,078-102,079,079AC/GA p.D59G;
hg18). RAB40AL encodes a small Ras-like GTPase
protein with one suppressor of cytokine signalling box.
The p.D59G variant is located in a highly conserved
region of the GTPase domain between b-2 and b-3
strands. Using RT-PCR, the authors show that RAB40AL
is expressed in human fetal and adult brain and kidney,
and adult lung, heart, liver and skeletal muscle. RAB40AL
appears to be a primate innovation, with no orthologues
found in mouse, Xenopus or zebraﬁsh. Western analysis
and ﬂuorescence microscopy of GFP-tagged RAB40AL
constructs from transiently transfected COS7 cells show
that the D59G missense change renders RAB40AL
unstable and disrupts its cytoplasmic localisation.
Conclusions This is the ﬁrst study to show that
mutation of RAB40AL is associated with a human
disorder. Identiﬁcation of RAB40AL as the gene mutated
in MPS allows for further investigations into the
molecular mechanism(s) of RAB40AL and its roles in
diverse processes such as cognition, hearing and skeletal
development.
INTRODUCTION
Mutations in genes encoding Ras proteins are
responsible for a number of human genetic disor-
ders, including Costello (HRAS), Noonan
(KRAS and NRAS), cardiofaciocutaneous (KRAS)
and autoimmune lymphoproliferative (NRAS)
syndromes.
1 2 Ras proteins are components of the
Ras/mitogen-activated protein kinase pathway and
are important for proper cellular growth, differen-
tiation and proliferation. Ras proteins canonically
cycle (or switch) between active guanosine
triphosphate (GTP)-bound and inactive guanosine
diphosphate (GDP)-bound conformations (Ras-
GTP and Ras-GDP).
3 Ras proteins generate distinct
signal outputs in cells, despite interacting with
a common set of competing activators (GTPase
activating proteins) and exchange factors (guanine
nucleotide exchange factors) which regulate Ras-
GTP levels.
45Ras proteins contain a hypervariable
(HVR) domain within the C-terminal 25e50
amino acids. The HVR contains sites for post-
translational lipid and other modiﬁcations and is
the only region that differs signiﬁcantly in sequence
among the otherwise highly homologous Ras genes.
HVR domains confer distinct biochemical proper-
ties of the Ras proteins and are involved in subcel-
lular localisation and signal transduction. Cell- and
tissue-speciﬁc expression may also contribute to the
unique biological and developmental effects of Ras
proteins.
6
Rab GTPases belong to the Ras superfamily of
small GTPases.
7 More than 50 Rab proteins have
been described in mammalian cells, each with
a speciﬁc subcellular localisation and many with
speciﬁc patterns of tissue distribution.
89Rab
proteins are involved in regulating intracellular
vesicle transport and trafﬁcking of proteins
between organelles, behaving as membrane-associ-
ated molecular switches.
89The suppressor of
cytokine signalling (SOCS) box distinguishes the
four Rab40 proteins (Rab40a, Rab40al, Rab40b and
Rab40c) from other Rab GTPases. SOCS box-
containing proteins interact with an E3 ubiquitin
ligase complex (with elongins B and C) that poly-
ubiquitinates target proteins for subsequent degra-
dation.
10 The target speciﬁcity of the complex is
determined by a proteineprotein interaction
domain located N-terminal of the SOCS box-
containing protein.
10 RAB40AL is a 278-amino acid
Ras-like GTPase protein with a single SOCS box
immediately proximal to the C-terminal HVR
domain.
RAB40AL (RLGP) was previously implicated in
a male person with an inversion (46,X,inv(X)
(p21.2q22.2)) disrupting the RAB40AL promoter
region.
11 This individual was diagnosed with
congenital muscular dystrophy accompanied by
severe intellectual disability, congenital nystagmus
and athetosis. He never developed meaningful
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Developmental defectsspeech nor sat without support, and died at 18 years of age from
suffocation due to tracheal obstruction. He was also diagnosed
with congenital Duchenne-type muscular dystrophy and
harboured a deletion of DMD exons 43e60, but his severe
intellectual disability was ascribed to the disruption of RAB40AL
function.
11 The authors hypothesised that RAB40AL may play
a critical role in the development or function of the central
nervous system (CNS) by transducing signals or transporting
molecules across mitochondrial membranes.
11
MartineProbst syndrome (MPS; MIM 300519) is a rare multi-
organ system neurodevelopmental disorder initially charac-
terised in three related male subjects with sensorineural hearing
loss, cognitive impairment, short stature and craniofacial
dysmorphisms.
12 MPS shares some characteristics with Costello
syndrome (CS) and Noonan syndrome (NS) such as short
stature, cognitive impairment and craniofacial dysmorphisms.
However, unlike CS and NS, individuals with MPS also exhibit
sensorineural hearing loss, renal insufﬁciency and impaired
haematopoiesis.
12 13 Additional clinical features seen in one
individual with MPS (patient 1 in Martin et al,
12 same as indi-
vidual II-1 in ﬁgure 1A) include chronic dyspnoea, pulmonary
hypertension, septal cirrhosis and abnormal branching patterns
of large hepatic vessels (unpublished data). The causative
mutation for MPS was previously localised to a 68 megabase
common haplotype region on X chromosome containing 683
genes between DXS1003 and DXS1220 (chrX:46,419,359-
114,514,483; hg18; Xp11.3-Xq23).
12 13 Deletions >1kb were
excluded by PCR.
12 13 Candidate genes COL4A5, DIAPH2,
POU3F4, ATRX, TIMM8A, XNP, ALEX2, KCNE1L and UBE1,
located within the 68 megabase target region, were previously
excluded by direct sequencing or dHPLC.
12 13 Female carriers in
the pedigree have been found to exhibit non-random (or skewed)
X-inactivation.
13 Here we provide evidence that a germline
missense mutation in RAB40AL leads to MPS.
MATERIALS AND METHODS
DNA samples from individuals were obtained with informed
consent as approved by the Institutional Review Board for
Human Subject Research at the University of Michigan Medical
Center.
Variant discovery and analysis via massively parallel sequencing
We performed whole genome sequencing (WGS), whole exome
sequencing (WES) and X chromosome-speciﬁc exome
14 15
sequencing to identify the causative mutation in MPS (see
Supplemental Methods for detailed methods). It should be
acknowledged that the word ‘whole’, used here in the context of
massively parallel sequencing, does not imply absolute and
complete coverage of all human genomic or exonic sequences.
Figure 1 RAB40AL p.D59G variant
analysis and segregation. (A) The
p.D59G variant identiﬁed in the
sequenced individuals (III-5 and IV-1)
segregates with the phenotype in the
family. For individuals with a red dot,
p.D59G was identiﬁed by Sanger
sequencing. Affected individuals are
shown in blue. For individuals with
a green dot, p.D59G status was not
determined. (B) Sequence
chromatograms showing the two
consecutive nucleotide changes
(AC/GA) in a male subject
(hemizygous) affected with MPS and an
unaffected obligate female carrier
(heterozygous). This change results in
an Asp to Gly change at codon 59.
Sanger sequencing readouts are shown.
(C) The p.D59G variant (red) lies within
a highly conserved 37 amino acid
region of the GTPase domain and is
conserved from humans to mosquitoes.
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Developmental defectsCoverage is limited by the repetitive nature and %GC content of
the target genomic regions and by the actual probes used in the
various exonic capture methods or reagents used. Reads from all
three sequencing strategies were aligned to the reference human
genome (UCSC hg18) using BWA.
16 For whole exome and whole
genome data, SAMTools
17 was used to remove duplicate reads
and call single nucleotide variants (SNVs) and indels. For
X chromosome exome data, duplicate sequences were removed
using PICARD and quality scores were recalibrated and variants
called using GATK.
18 SNVs with a Phred quality score #30 or
<43 coverage were excluded. SNVs were ﬁltered through
dbSNP130 and then imported into SeattleSeq for variant anno-
tation. Variants were further ﬁltered to exclude those identiﬁed
by the 1000 Genomes Project (March 2010 release) or the
National Heart, Lung, and Blood Institute Exome Sequencing
Project. Predictions of functional effect of the missense variants
were performed using PolyPhen,
19 PolyPhen-2,
19 MuPro,
20
SIFT
21 and AlignGVGD.
22 23 Measurements of the evolutionary
conservation of the nucleotide were performed by GERP (from
the original SeattleSeq annotation) and PhyloP. The Grantham
matrix score was used to measure how different the two amino
acids (wildtype vs mutant) are to each other.
24 Candidate genes
with fetal nervous system expression (see the URL under Web
resources) were veriﬁed by PCR/Sanger sequencing (data not
shown).
Tissue expression
Clontech Multiple Tissue cDNA (Clontech, Mountain View,
California, USA) panels from human fetal (Cat. #: 636747) and
adult (Cat. #: 636742) tissues were used for expression analysis.
Per Clontech certiﬁcate of analysis, the cDNA panels were
generated from poly A+ RNA from the various tissues with
assurance of original DNA contamination of <0.01% by pico
green staining. Five ml( w5 ng) of cDNA was mixed with 10 ml
each (5 mM) of forward and reverse primers with 25 mlo f2 3
PCR Master mix (Cat. #: M7502; Promega, Madison, Wisconsin,
USA). RAB40AL speciﬁc primers 59 GCCTGCAGGACGG-
CACGGCC 39 and 59 TCCCTCTTCCAGGTGTAACCATT 39
were used along with human b-actin gene (ACTB) primers 59
ATATCGCCGCGCTCGTCGTC 39 and 59 AGTGGTACGGC-
CAGAGGCGT 39. PCR conditions were 958C for 2 min, followed
by 30 cycles of 958C for 30 s, 608C for 1 min, 728C for 1 min, and
728C for 5 min. The PCR product was analysed by agarose gel
electrophoresis.
GFP expression vector construction
pmCITeC1 and pmCITeN1 vectors (derivatives of Clontech
pEGFPeC1 and eN1 vectors)
25 were used for generating
expression constructs with RAB40AL tagged with green ﬂuo-
rescent protein (GFP). Standard molecular biology techniques
were employed for engineering the constructs. The single exon
RAB40AL was PCR ampliﬁed from human male control or
patient DNA using primers 59 AGATCTATGAGCGCCCCGGG
CAGCCCCGAC 39 and 59 GTCGACTTAAGAAATTTTGCAG
CTGTTTCT 39,o r5 9 CTCGAGATGAGCGCCCCGGGCAGCC
CCGAC 39 and 59 AAGCTTAGAAATTTTGCAGCTGTTTCT 39
(restriction sites underlined). The ﬁrst primer set engineers BglII
and SalI restriction sites at the 59 and 39 ends of the PCR
product, respectively. These sites allow for inframe cloning of
GFP and RAB40AL wild type or p.D59G variant coding sequence
in pmCITeC1 to generate N-terminal fusions. The second set of
primers engineers XhoI and HindIII restriction sites at the 59
and 39 ends of the PCR products. These PCR products
were cloned into pmCITeN1 to generate C-terminal inframe
fusions of GFP to RAB40AL wild type or p.D59G variant. We
used GFPeRAB40AL and GFPeRAB40ALep.D59G to denote
the N-terminal tagged constructs, and RAB40ALeGFP and
RAB40ALep.D59GeGFP to denote C-terminal tagged
constructs. Vector constructs were conﬁrmed by Sanger
sequencing for proper engineering and sequence accuracy.
Transfection and immunocytochemistry
COS7 cells were grown in DMEM with 10% FBS in a 12-well
plate on round coverslips. At w90% conﬂuence, transfection
was performed with lipofectamine 2000 (Invitrogen, Carlsbad,
California, USA). Speciﬁcally, 2 mg of vector DNA in water was
diluted in 100 ml of Opti-MEM reduced serum media (GIBCO,
Carlsbad, California, USA) for 5 min at room temperature. In
addition, 5 ml of lipofectamine reagent was mixed with 100 mlo f
Opti-MEM reduced serum media and incubated for 5 min at
room temperature. Both solutions were then combined and
incubated for 20 min at room temperature. Subsequently, an
additional 300 ml of Opti-MEM reduced serum media was added
to the mix and the total volume then added to cells and incu-
bated at 378C for 4 h. Subsequently, 500 ml of DMEM with 10%
FBS was added to the coverslips and cells incubated at 378C for
48 h. Cells were then ﬁxed with ice-cold methanol for 5 min, air
dried, washed with PBS followed by two washes with PBS/
Tween 20 (0.1%) 5 min each, and then treated with 1:500 dilu-
tion of mouse anti-human mitochondrial COXIV antibody
(Cat. #: mAbcam33985; Abcam, Cambridge, Massachusetts,
USA) and incubated overnight at 48C. Following two more
washes with PBS/Tween-20, Alexa Fluor 555 F(ab’)2 fragment of
goat antimouse IgG (Cat. #: A21425; Invitrogen) diluted 1:500
was added and incubated for 1 h at room temperature. Following
two additional washes, cells were stained with DAPI (1:500
dilution in PBS), mounted and images captured on a Leica
DM5000B microscope (W. Nuhsbaum Inc., McHenry, Illinois,
USA). Transfection efﬁciencies were measured by determining
the percentage of GFP+ cells among total DAPI+ cells trans-
fected with vector only, WT construct or MUT construct.
Nuclear clustering percentages were measured by determining
the percentage of cells with fusion protein within the nucleus,
nucleolus and/or perinuclear regions among all GFP+ cells.
Cell lysate preparation, PAGE and western analysis
Conﬂuent COS7 cells in 12-well tissue culture plates were
washed twice with ice-cold PBS and treated with 500 ml of RIPA
buffer (Cat. #: R0278; Sigma, St. Louis, Missouri, USA) with 1%
Protease Inhibitor Cocktail BD BaculoGold (Cat. #: 554779; BD
Biosciences, San Diego, California, USA). After thoroughly
mixing, the cell suspension was incubated on ice for 20 min with
additional vortexing for complete lysis. The suspension was
sonicated for 10 min and then centrifuged at 13000 rpm for
5 min. The supernatant was collected and quantiﬁed using Bio-
Rad Protein Assay kit (Cat. #: 500-0006; Bio-Rad, Hercules,
California, USA). Approximately 30 mg of protein was added to
5 ml of NuPAGE sample buffer (Cat. #: NP0007; Invitrogen)
along with 2 ml of NuPAGE reducing agent (Cat. #: NP0004;
Invitrogen). The sample mix was heated for 10 min at 808C.
Precast Invitrogen NuPage 4e12% Bis-Tris gels (Cat. #:
NP0322BOX; Invitrogen) were used for polyacrylamide gel
electrophoresis (PAGE). NuPAGE antioxidant (0.25%) (NP0005;
Invitrogen) was added to 200 ml of 1X MOPS (Cat. #: NP0001;
Invitrogen) running buffer and poured in the centre of the
apparatus. Untreated 1X MOPS was used in the remaining
chamber. The gel was run at 200 V for 1.5 h and proteins
transferred onto Immobilon PVDF transfer membranes
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Developmental defects(IPSN07852; Millipore, Billerica, Massachusetts, USA) using
NuPage Transfer buffer (Cat. #: NP0006-1; Invitrogen).
Membranes were blocked overnight at 48C with 5% BSA
prepared in tris-buffered saline. Subsequently, the membranes
were incubated for 2 h at room temperature with the primary
mouse anti-GFP monoclonal antibody (Cat. #: 632380; Clon-
tech) (or primary mouse anti-glyceraldehyde-3-phosphate
dehydrogenase monoclonal antibody for detecting control
house-keeping protein; Cat. #: MAB374, Millipore, Temecula,
California, USA) followed by ﬁve washes (5 min each) with
tris-buffered salinee0.5% Tween20. The membrane was then
incubated with secondary anti-mouse horseradish peroxidase-
conjugated antibody (Cat. #: 1858415; Pierce/Thermo Scientiﬁc,
Rockford, Illinois, USA) for 1 h at room temperature. Washes
were repeated and protein was detected using the chem-
iluminescence system (Cat. #: 34087; Thermo Scientiﬁc).
Statistical analysis of data
The SPSS Statistics program V.19 was used for statistical anal-
ysis of data. A general linear model was performed to examine:
(1) transfection efﬁciencies (number of GFP+ cells/number of
DAPI+ cells) among the three vectors and (2) the number of
transfected cells with clustering of GFP ﬂuorescence signal
within the nucleus, nucleolus and/or perinuclear regions for the
three vectors. Post hoc comparisons were performed to deter-
mine differences among the three groups with a Bonferroni
correction.
RESULTS
RAB40AL is mutated in MPS
WGS, WES and X chromosome speciﬁc exome sequencing were
performed to analyse DNA from two related male subjects
affected with MPS (WGS, WES and X exome sequencing were
performed for individual III-5, and X exome sequencing only was
performed for individual IV-1; see table 1 and ﬁgure 1A). The
average read depths per target region were 4.8X and 10.9X for
WGS and WES, respectively, and 86.9X (for III-5) and 17.9X (for
IV-1) for X-speciﬁc exome sequencing. Combining all three
massively parallel sequencing strategies provided complete
sequence coverage for 96.4% (3496/3625) of exons with $43
depth of coverage. Sixty-one of the remaining 129 exons were
not covered by the three different sequencing strategies, yet
were expressed in the fetal nervous system; the other 68 exons
were not expressed in the human fetal nervous system and were
excluded from further analysis. Forty-four of the remaining 61
exons were Sanger sequenced and revealed no potentially
damaging or pathogenic variants (Supplemental table 1).
Seventeen exons proved difﬁcult to sequence after multiple
ampliﬁcation attempts with different PCR primer pairs,
presumably due to their high repetitive sequence nature and/or
higher GC content.
Massively parallel sequencing analysis identiﬁed 15 candidate
variants in 10 genes common to III-5 and IV-1 (table 1). Two
genes, RAB40AL and ARHGEF9, contained missense mutations.
Application of multiple protein function prediction algorithms
showed the RAB40AL p.D59G variant (102,079,078-
102,079,079AC/GA, hg18) to be highly damaging (table 1 and
Supplemental table 2), while the ARHGEF9 p.D306E variant
(62,810,649G/C, hg18) was not considered damaging.
RAB40AL was covered 100% with optimum coverage noted
using the X-speciﬁc exome sequencing strategy (Supplemental
ﬁgure 1.
The RAB40AL p.D59G variant segregated with the phenotype
in MPS family members (ﬁgure 1A), and all obligate and non-
obligate female subjects with X chromosome skewing were
carriers of the mutation.
13 The AC/GA change in hemizygous
male subjects and heterozygous female subjects and the
resulting D59G amino acid substitution are shown in ﬁgure 1B.
Asp59 (D59) is highly conserved from humans to mosquitoes
(ﬁgure 1C). There were no p.D59G variants detected after: (a)
direct sequencing of 297 neurologically normal control male
subjects (250 of 297 were Caucasian) obtained from the
Greenwood Genetic Center, National Institute of Neurological
Disease and Coriell Institute for Medical Research and (b)
analysis of the most recent 1000 Genomes Project dataset or the
National Heart, Lung, and Blood Institute Exome Sequencing
Project (w3000 individuals of unknown gender; 10/2011
accessed). Based on published analytical approaches,
26 this
number of controls provides >95% power to exclude RAB40AL
p.D59G as a normal sequence variant with 0.1% frequency.
RAB40AL appears to be a primate innovation
In mammals, X chromosome genes maintain complete synteny
because of the constraints imposed by X chromosome inacti-
vation; however, some non-pseudoautosomal X chromosome
genes violate this rule.
27 Detailed analysis of the corresponding
syntenic region identiﬁed RAB40AL orthologues in primates such
as rhesus monkeys and chimpanzees, but not in dog, rat, mouse,
Xenopus or zebraﬁsh (data not shown). Nucleotide- (using both
59- and 39-UTR regions as well as the complete gene) and
protein-BLASTanalyses of RAB40AL and RAB40AL, respectively,
identiﬁed mouse Rab40b as the gene product with the highest
identity (83%) and similarity (91%) to human RAB40AL;
however, the orthologue of Rab40b on mouse chromosome 11 is
Table 1 Summary of whole genome, whole exome and X chromosome speciﬁc exome sequencing for two affected related individuals
Individual III-5 Individual IV-1
Shared variants Whole genome Whole exome X exome X exome
Total variants 2647939 45182 1718 1197 e
Novel variants 251039 7869 300 192 e
Variants in haplotype block 3599 34 137 90 e
NS/MS/SS/UTR 27 9 25 18 15
Fetal nervous system expressed ee e e7
Conﬁrmed by sanger sequencing ee e e2
Predicted damaging ee e e1
The number of variants for each step in the analysis pipeline for the three distinct sequencing methods is shown. There were a total of 15 variants covering 12 genes shared among the two
individuals (SSX4, FOXR2, RAB40AL, GRIPAP1, CLCN5, FOXR2, SPIN3, ARHGEF9, FAM123B, KIAA2022, AR, TRPC5). Of these 12 genes, seven were expressed in the fetal nervous system
(GRIPAP1, CLCN5, SPIN3, ARHGEF9, FAM123B, KIAA2022, RAB40AL) and two of these genes (ARHGEF9 and RAB40AL) contained missense mutations and segregation with the phenotype in
the family.
MS, missense; NS, nonsense; SS, splice site; UTR, untranslated region.
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Developmental defectsRAB40B on human chromosome 17 (ﬁgure 2; conﬁrmed by
synteny analysis). Human RAB40A shows 99% protein identity
and similarity to RAB40AL; the RAB40A gene is w560 kb telo-
meric to RAB40AL on the X chromosome and is ﬂanked by
repetitive sequences. The phylogenetic relationship of the
RAB40 family of proteins is shown in ﬁgure 2. The apparent
restriction of RAB40AL to primates suggests a recent evolu-
tionary divergence and is consistent with the hypothesised
functional role of RAB40AL in neurodevelopment.
RAB40AL is expressed in fetal and adult human tissues including
brain and kidney
Because individuals with MPS exhibit developmental delay and
cognitive impairment, we hypothesised that RAB40AL should be
expressed in both fetal and adult brain tissues. Analysis of RNA
from fetal and adult human tissues using RT-PCR showed that
RAB40AL is expressed in MPS-related tissues, including brain and
kidney (ﬁgure 3), consistent with reported MPS phenotypes.
12
Based on this semiquantitative PCR-based expression analysis,
RAB40AL expression levels in the fetal lung, heart, liver and
skeletal muscle appeared lower than in adult tissues (ﬁgure 3),
but this needs to be conﬁrmed by quantitative methods. Others
have also shown, by northern analysis, that RAB40AL is
expressed in adult brain, heart, liver, skeletal muscle and
kidney.
11
The D59G missense change alters RAB40AL abundance in COS7
cells
Based on the location of D59 within the GTPase domain of
RAB40AL, speciﬁcally within a conserved loop region located
between two presumptive b-strands, we predicted that the
D59G missense mutation might render it unstable, reducing
function. The C-terminal HVR of RAB40AL contains sequence
motifs that mediate attachment of lipid moieties predicted to
anchor it to the phospholipid bilayer. Consequently, an uncon-
strained C-terminus may be critical for normal RAB40AL bio-
logical function. To test this, we constructed N-terminal and
C-terminal GFP-tagged fusions of RAB40AL and RAB40ALe
p.D59G and examined the impact of p.D59G by transient
transfection and western analysis. Results of western analysis
using anti-GFP monoclonal antibody of whole cell lysates from
cells transiently transfected with these expression vectors are
shown in ﬁgure 4. Both GFP (control vector alone) and WT
GFPeRAB40AL were easily detected. In contrast, MUT
GFPeRAB40ALep.D59G fusion protein was signiﬁcantly
reduced compared with WT, despite similar transfection efﬁ-
ciencies (see table 2). We hypothesise that the reduced abun-
dance of GFPeRAB40ALep.D59G is due to instability and
degradation of the fusion protein.
We observed low abundance bands from both RAB40ALeGFP
and RAB40ALep.D59GeGFP constructs, despite similar trans-
fection efﬁciencies (data not shown). The low abundance of
RAB40ALeGFP fusion protein suggests that constraining the
RAB40AL C-terminus with a bulky (w27 kDa GFP) protein
disrupts RAB40AL function and renders it unstable. However,
further analyses are needed to directly measure RAB40AL
synthesis and degradation kinetics.
The D59G missense change disrupts RAB40AL cytoplasmic
localisation
Previous studies have shown that RAB40AL localises to the
mitochondria in COS7 cells.
11 In addition, analysis of the
C-terminal 49 amino acid HVR of RAB40AL by MitoPred,
a mitochondrial prediction algorithm, predicted mitochondrial
localisation with 99% conﬁdence (data not shown). This was
not the case for Xenopus Rab40c or human RAB40C, where the
Figure 2 Phylogenetic relationship of RAB40 family of proteins.
Dendogram generated from protein sequences aligned using CLUSTAL
W V.2.1 is shown. Synteny analyses of RAB40AL and RAB40A using
UCSC Genome Browser did not identify mouse, Xenopus or zebraﬁsh
orthologues of human RAB40AL. The X-linked RAB40AL and RAB40A are
unique to primates (red rectangle). Un, unknown. Figure 3 RAB40AL expression in relevant fetal and adult human
tissues. RT-PCR using Clontech multiple tissue cDNA panels from human
fetal and adult tissues shows high RAB40AL expression in fetal and adult
brain and kidney tissues, with lower levels of expression in fetal lung,
heart, liver and skeletal muscle. Single bands corresponding to 812 bp
and 437 bp for RAB40AL and beactin PCR products, respectively, were
observed as expected. Bands were also conﬁrmed by Sanger
sequencing. A, adult; F, fetal.
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Developmental defectsformer is known to be localised to the Golgi.
28 Consequently, we
examined whether the p.D59G variant disrupts this mitochon-
drial localisation (ﬁgure 5 and Supplemental ﬁgure 2). As
expected, GFPeRAB40AL localised to the mitochondria but
was also found diffusely throughout the cytoplasm (ﬁgure 5,
panel H). This cytoplasmic localisation was disrupted in
GFPeRAB40ALep.D59G constructs and the fusion protein
appeared to be accumulated or clustered within the nucleus,
nucleolus and/or perinuclear region (ﬁgure 5, panels I and L).
One-way ANOVA revealed that cells transfected with V, WTand
MUT constructs were signiﬁcantly different on ‘nuclear clus-
tering’ efﬁciency (F2,26 ¼ 41.074, p<0.001). Pairwise post hoc
comparison indicated that cells transfected with the MUT
construct (64.0616.9; mean6SD) were signiﬁcantly different
than those transfected with WT (30.1616.2; mean6SD) for per
cent nuclear clustering (p<0.001) (see also table 2). Interestingly,
the C-terminal GFP-tagged fusions (RAB40ALeGFP and
RAB40ALep.D59GeGFP) exhibited staining patterns similar
to the N-terminal tagged mutant fusion construct
(GFPeRAB40ALep.D59G) (compare panels I and L in Supple-
mental ﬁgure 2 with panel L in ﬁgure 5). Thus, the D59G
missense change appears to disrupt the normal localisation of
RAB40AL, perhaps via mechanism that also render it prone to
degradation (ﬁgure 4). These data also suggest that
the RAB40AL C-terminus is critical for protein stability and
intracellular protein localisation.
DISCUSSION
We have identiﬁed a germline missense RAB40AL mutation
(p.D59G) in individuals affected with MPS. This variant is
predicted to be damaging using seven different DNA/protein
functional inference algorithms, is absent in w3300 normal
controls, segregates with the phenotype in the family and is
located within a highly conserved GTPase region of the protein.
RAB40AL is expressed in fetal and adult brain tissues, consistent
with the cognitive impairments present in MPS individuals.
Functional analysis of the p.D59G variant by transfection
studies and western blotting showed that the variant renders
the protein unstable and disrupts its normal cytoplasmic local-
isation. An unconstrained C-terminus appears necessary for
normal RAB40AL localisation, based on transient transfections
of N-terminal and C-terminal tagged wild type and mutant
fusion constructs. We conclude that disruption of RAB40AL
function by the p.D59G variant leads to MPS.
XLID, X- linked hearing loss and X-inactivation
MPS is one among approximately 200 X- linked intellectual
disability (XLID) disorders.
29 The prevalence of XLID is
approximately 1:1000 in male subjects, and XLID accounts for
w16% of male subjects with intellectual disability.
29 30 Among
the 1606 genes on the human X chromosome (Build 37.1), at
least 87 have been identiﬁed as causative for XLID.
29 31 32 Several
genes encoding GTP-binding proteins are reported to play critical
roles in the development and function of the CNS, including
several that participate in intracellular signalling or vesicular
trafﬁcking.
33e37 Data reported here support the hypothesis that
RAB40AL is critical for normal development and function of
CNS and RAB40AL can now be added to the list of syndromic
XLID causative genes.
In addition to cognitive impairments, individuals with MPS
have bilateral congenital sensorineural hearing loss.
12 X- linked
forms of hearing loss account for w5% of all congenital hearing
loss, and at least eight different causative genes have been
described (DFN1/TIMM8A, DFN2/PRPS1, DFN3/POU3F4, DFN6/
SMPX, DFN7/GSTP1, NDP, FLNA and MED12).
12 29 Mutations in
TIMM8A, which encodes a mitochondrial intermembrane protein
that interacts with a GTPase to regulate programmed cell death,
causes MohreTranebjaerg/deafnessedystonia syndrome.
38 Inter-
estingly, several autosomal-linked small GTPase proteins,
including the Rho GTPases, also contribute to hearing pheno-
types.
39 40 To our knowledge, ours is the ﬁrst study to show that
mutation of RAB40AL is associated with hearing loss.
X-inactivation equalises the dosage between male and female
subjects for most X chromosome genes, and this process is
Figure 4 Reduced abundance of green ﬂuorescent protein (GFP)e
RAB40ALep.D59G fusion protein in COS7 cells. Western analysis of
whole cell lysates from cells transiently transfected with GFPeRAB40AL
vector constructs (V, vector only; WT, GFPeRAB40AL; or MUT,
GFPeRAB40AL p.D59G) using anti-GFP (or anti-GAPDH) monoclonal
antibody (mAb). Results show reduced abundance of
GFPeRAB40ALep.D59G fusion protein, with essentially unchanged
levels of the house-keeping GAPDH protein. Transfection efﬁciencies
were not signiﬁcantly different among the three vector constructs (see
table 2). COS, untransfected COS7 cell lysate.
Table 2 Quantitative analysis of transfection experiments
V WT MUT F2,26 p Value
Transfection efﬁciency mean (SD) 42.1 (5.9) 44.7 (5.4) 41.1 (14.3) 0.434 0.653
Total DAPI cells counted 1530 1595 1841
% Nuclear clustering mean (SD) 1.9 (2.1) 30.1 (16.2) 64.0 (16.9) 41.074 <0.001
Total GFP cells counted 627 692 715
N8 9 1 2
ANOVA analysis was performed to determine the F and p values, and post hoc comparisons were performed to determine differences among the three groups with a Bonferroni correction
(see text).
GFP, green ﬂuorescent protein; MUT, GFPeRAB40ALep.D59G; N, number of experiments; V, vector only; WT, GFPeRAB40AL SD, standard deviation.
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mutations and genomic alterations, the X chromosome bearing
the altered gene or genomic region in female subjects is prefer-
entially inactivated. Exceptions to this rule include cases where
an X chromosome is translocated onto an autosome.
41 In MPS,
four obligate and four non-obligate female heterozygous D59G
mutation carriers show skewed X-inactivation and are clinically
unaffected.
12 13 Interestingly, the unaffected mother of the male
individual described by Saito-Ohara et al (2002)
11 was a carrier of
the same inversion (46,X, inv(X)(p21.2q22.2)) but her X-inacti-
vation status was not reported. Consequently, X chromosome
inactivation skewing correlates with heterozygosity for the
p.D59G variant and is another useful indicator of carrier status
in MPS.
The RAB40AL p.D59G variant
Insights into the potential effect of D59G on RAB40AL function
can be gained by examining the characteristics of the D47
aspartate residue (equivalent to RAB40AL D59) relevant for Rac
other Ras-like proteins. D47 is predicted to be highly relevant for
Rab function.
42 In addition to the known canonical function of
GTPases of cycling between two states (ie, GDP vs GTP bound),
phosphorylation of speciﬁc C-terminal serine residues in Ras
proteins is thought to act as an allosteric discriminator of
conformational/dynamic states. Phosphorylation inﬂuences
effector protein interactions with the GTPase protein at the
switch loops/effector domain.
43 D47 in HRAS and RAP1B
(another Ras-like protein) is located between the conserved b-2
and b-3 strands, and appears to be involved in facilitating this
switch in conformational/dynamic states (from inactive to
active) following S179 phosphorylation in the HVR domain.
43
Removal of D47 or E49 in HRAS negatively inﬂuences Ras
signalling and orientation in the membrane.
44 The p.D59G
variant may disrupt protein folding, nucleotide-binding (conse-
quently, GTPase activity) or localisation rendering the protein
non-functional and prone to degradation.
The Rab40 family
Current knowledge of the characteristics and roles of the various
Rab40 proteins is limited. To date, the best characterised of the
Rab40 proteins are the Rab40c family members. In Xenopus,
Rab40c is required for normal gastrulation and embryogenesis.
28
Rab40c is localised at the Golgi apparatus and interacts with
ElonginB/C and Cullin5 to form a ubiquitin ligase complex that
selectively polyubiquitinates Rap2 and regulates non-canonical
Wnt signalling.
28 In rat, Rab40c is expressed in oligodendrocytes
Figure 5 p.D59G disrupts normal intracellular protein localisation. Cells transiently transfected with N-terminal green ﬂuorescent protein (GFP)-tagged
vector constructs (vector control, A-D; RAB40AL, E-H; and RAB40AL p.D59G, I-L) and stained with anti-mitochondrial COXIV antibody (Mito Ab) and
DAPI are shown. GFPeRAB40AL localises to the mitochondria and throughout the cytoplasm (panel H), while this localisation is disrupted with
GFPeRAB40ALep.D59G (panel L). GFPeRAB40ALep.D59G appears to be accumulated or clustered within the nucleus, nucleolus and/or perinuclear
region (panels I and L). Representative transfected cells are shown (arrows).
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45
Human RAB40C is regulated directly by a cancer-related
miRNA, let-7a, and mediates the biological effects of let-7a in
gastric tumorigenesis.
46 Thus, Rab40c proteins have diverse
functions in embryogenesis, ubiquitination and cancer.
In contrast to Rab40c, Rab40a and Rab40b function and
intracellular localisation remain to be determined. Rab40b is
expressed in the zebraﬁsh brain (zebraﬁsh database), suggesting
a role in neurodevelopment. We found that mouse Rab40b is
expressed in E14.5 embryonic and adult mouse brain, inner ear
and heart tissues (data not shown). It remains to be determined,
however, whether humans with mutated RAB40B also exhibit
cognitive impairment and hearing loss, similar to individuals
with MPS.
Unlike RAB40C and RAB40B, RAB40A and RAB40AL appear to
be primate innovations (ﬁgure 3). A key approach for identifying
orthologues of human genes in other species is synteny analysis,
that is, exploiting the gene order conservation between
species.
47 48 This approach identiﬁed orthologues of RAB40AL in
primates only. Interestingly, primate speciﬁc genes display
distinctive features including high tissue speciﬁcity, rapid
evolution and short peptide size.
48 Some primate-speciﬁc genes
are thought to have been formed by gene duplication.
48 and
transposable elements also appear to play an important role.
48 49
Whether gene duplication or transposon-mediated events gave
rise to RAB40AL in primates is not clear. There are at least several
hundred genes that differ between human and mouse, most as
a result of gene duplications or deletions.
50 51 The extent to
which RAB40AL function overlaps with the other Rab40
members or is unique to primates is currently unknown. Study
of the paralogue of RAB40AL (Rab40b) or introduction of human
RAB40AL mutations into the mouse may provide insights into
the roles of RAB40B, RAB40A and RAB40AL in brain, inner ear
and other organ development.
SUMMARY
Using comprehensive variant discovery by high-throughput
sequencing, we have identiﬁed RAB40AL p.D59G in the multi-
organ system neurodevelopmental disorder MPS. The speciﬁc
signalling pathway for RAB40AL and its particular mechanism
and function in the mitochondria remain to be elucidated.
Identiﬁcation of RAB40AL mutations allows for detailed inves-
tigations into its molecular mechanism and functions in MPS,
and should help improve diagnosis and treatment of individuals
with related phenotypes.
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